ALK-Positive Lung Non-Small Cell Carcinoma

ALK-Positive Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Guangdong Association of Clinical Trials
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07491497	A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC	recruiting	Phase 1 / Phase 2	160	TRIANA Biomedicines, Inc.INDUSTRY	2	Sep 3, 2026	clinicaltrials
NCT06092086	Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC	recruiting	Phase 2	126	Guangdong Association of Clinical TrialsOTHER	1	Oct 23, 2023	clinicaltrials